Get the Stockscreener App
29.03
70.87%
12.04
After Hours:
28.36
-0.67
-2.31%
Evommune Inc stock is traded at $29.03, with a volume of 15.93M.
It is up +70.87% in the last 24 hours and up +44.21% over the past month.
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.
See More
Previous Close:
$16.99
Open:
$29.52
24h Volume:
15.93M
Relative Volume:
34.72
Market Cap:
$915.14M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+57.09%
1M Performance:
+44.21%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$21.80
$33.20
1-Week Range:
$15.97
$33.20
52-Week Range:
$13.88
$33.20
Evommune Inc Stock (EVMN) Company Profile
Name
Evommune Inc
Sector
Industry
Phone
(650) 223-7745
Address
1841 PAGE MILL RD, PALO ALTO
Compare EVMN vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EVMN
Evommune Inc
|
29.03 | 535.59M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.48 | 119.47B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.91 | 82.49B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.16 | 51.25B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.98 | 42.28B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
353.43 | 38.60B | 4.98B | 69.60M | 525.67M | 0.5198 |
Evommune Inc Stock (EVMN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-22-26 | Initiated | Oppenheimer | Outperform |
| Jan-08-26 | Initiated | Raymond James | Strong Buy |
| Jan-06-26 | Initiated | H.C. Wainwright | Buy |
| Dec-01-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-01-25 | Initiated | Evercore ISI | Outperform |
| Dec-01-25 | Initiated | Leerink Partners | Outperform |
| Dec-01-25 | Initiated | Morgan Stanley | Overweight |
| Dec-01-25 | Initiated | William Blair | Outperform |
View All
Evommune Inc Stock (EVMN) Latest News
H.C. Wainwright maintains Buy for EVMN Evommune Inc Feb 10 2026 - Meyka
Evommune, Nektar soar on atopic dermatitis phase II data - BioWorld MedTech
Evommune’s Atopic Dermatitis Data Competitive With Dupixent - Citeline News & Insights
Evommune Starts Making Case to Challenge Dominance of Sanofi’s Dupixent in Atopic Dermatitis - MedCity News
Health Care Stocks Split As Evommune Pops On Eczema Data - Finimize
EVMN Stock Rating: Analyst Mitchell S. Kapoor Raises Price Targe - GuruFocus
Evommune stock price target raised to $55 by Evercore ISI on positive trial data By Investing.com - Investing.com India
Evommune (NYSE:EVMN) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
Evommune stock price target raised to $55 by Evercore ISI on positive trial data - Investing.com
Evommune (NYSE:EVMN) Sets New 1-Year HighHere's What Happened - MarketBeat
Why Is Evommune Stock Soaring Today?Evommune (NYSE:EVMN) - Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
This Biotech Stock Nearly Doubled In Value Today Morning – What’s Driving Investor Optimism? - Stocktwits
Evommune Stock Soars 51% Over Positive Top-Line Data From Atopic Dermatitis Study - Nasdaq
Evommune Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate - PharmiWeb.com
Evommune Soars as Dermatitis Treatment Rivals Dupixent in Mid-Stage Trial - BioSpace
Evommune Says Atopic Dermatitis Treatment Achieved 'Statistically Significant' Outcomes in Proof-of-Concept Trial; Shares Rise - marketscreener.com
Evommune wins in mid-stage trial for eczema drug (EVMN:NYSE) - Seeking Alpha
Evommune reports positive mid-stage data for eczema drug - statnews.com
EVMN: EVO301 achieved significant efficacy and safety in Phase 2a atopic dermatitis trial - TradingView
Evommune's Dupixent-like eczema data drive 75% stock rally - Fierce Biotech
Evommune Advances EVO301 After Positive Phase 2a Results - TipRanks
Evommune, Inc. Announces Positive Phase 2a Trial Results for EVO301 in Atopic Dermatitis - TradingView
Evommune soars on mid-stage atopic dermatitis data - FirstWord Pharma
Evommune stock soars after positive Phase 2a trial results for eczema drug - Investing.com UK
Evommune’s atopic dermatitis drug meets primary endpoint in phase 2a trial - Investing.com
Evommune reports EVO301 trial met primary endpoint - TipRanks
Evommune Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate-to-Severe Atopic Dermatitis - Yahoo Finance
Evommune (NYSE:EVMN) Stock Price Down 5.3%Time to Sell? - MarketBeat
Evommune (NYSE:EVMN) Trading 10% HigherWhat's Next? - MarketBeat
Evommune (NYSE:EVMN) Shares Down 6.9%Here's Why - MarketBeat
Biotech investor Cormorant secures $150M for another SPAC deal - BioPharma Dive
Evommune (NYSE:EVMN) Coverage Initiated by Analysts at Oppenheimer - Defense World
Oppenheimer Initiates Coverage of Evommune (EVMN) with Outperform Recommendation - Nasdaq
Evommune (NYSE:EVMN) Now Covered by Oppenheimer - MarketBeat
Evommune (NYSE:EVMN) Stock Price Up 7.7%Still a Buy? - MarketBeat
Evommune, Inc. (NYSE:EVMN) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
Evommune, Inc. Common Stock (NY: EVMN - The Chronicle-Journal
High Risk, High Reward: 3 Healthcare Stocks to Watch in 2026 - Finviz
Evommune, Inc. Common Stock (NYSE:EVMN) Stock Quote - FinancialContent
Evommune (NYSE:EVMN) Trading Down 7.7%Here's What Happened - MarketBeat
Evommune (NYSE:EVMN) Shares Gap UpWhat's Next? - MarketBeat
Evommune: Buy Rating Driven by Upcoming Phase II Readouts and Broad Inflammatory Disease Pipeline Potential - TipRanks
Raymond James Initiates Coverage on EVMN with Strong Buy Rating - GuruFocus
HC Wainwright Comments on Evommune FY2025 Earnings - MarketBeat
Raymond James initiates Evommune stock with Strong Buy rating, $40 target - Investing.com Nigeria
Evommune participates in a conference call with William Blair - MSN
Evommune’s EVO756 Trial Targets High-Need Urticaria Market: What Investors Should Watch - TipRanks
Evommune stock initiated with Buy rating at H.C. Wainwright on urticaria potential - Investing.com Nigeria
This Spire Global Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday - Benzinga
Evommune (EVMN) Receives 'Buy' Rating from HC Wainwright & Co. | - GuruFocus
Evommune Inc Stock (EVMN) Financials Data
There is no financial data for Evommune Inc (EVMN). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.36%
1.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):